TABLE 2.
Compound | BEI (%) | In vitro intrinsic Clbiliary (ml/min/kg)a | ||
---|---|---|---|---|
WT | TR− | WT | TR− | |
E2–17βG | 18.4 ±3.9 | 0.378 ±0.378 | 17.8 ±0.4 | 0.363 ±0.363 |
Olmesartan | 14.7 ±0.5 | 7.05 ±0.93 | 1.72 ±0.25 | 0.931 ±0.167 |
Valsartan | 18.9 ±2.6 | 1.63 ±1.33 | 3.24 ±0.51 | 0.406 ±0.341 |
Pravastatin | 43.4 ±2.3 | 10.7 ±3.4 | 4.43 ±0.75 | 1.13 ±0.33 |
Rosuvastatin | 44.9 ±6.1 | 20.6 ±3.9 | 46.1 ±0.4 | 21.2 ±6.0 |
Pitavastatin | 19.9 ±1.4 | 6.54 ±3.38 | 34.6 ±3.1 | 10.4 ±5.4 |
In vitro intrinsic Clbiliary values were calculated according to Equation (2) based on a 10-min incubation at concentrations of 1 μM for E2–17βG and 5 μM for all other compounds.